The acquisition of data from well-designed studies is desirable in the near future. 
Introduction

98
Hepatitis B virus (HBV) reactivation in haematological patients has been associated with 99 chemotherapy (CHT) interruption, frequent hospitalization, progression to hepatic failure 100 and death (1) . All of these conditions are largely preventable by the corrective measures of mortality rates (9-11).
185
Which antiviral drugs should be used to treat HBsAg-positive patients?
186
All HBsAg-positive patients, regardless HBV DNA levels, should receive anti-HBV drugs.
187
The efficacy of lamivudine is hampered by the development of mutations in the tyrosine- received lamivudine therapy because a certain rate of resistance is expected (20) . 
